- Novo Nordisk issues profit warning as competition — legal and otherwise — hits Wegovy, Ozempic MarketWatch
- Novo Nordisk shares plunge 17% after Wegovy-maker cuts full-year guidance CNBC
- Obesity drugmaker Novo Nordisk cuts 2025 sales growth, operating profit outlook Yahoo Finance
- Novo Lowers Forecast as Weight-Loss Drug Sales Fall Short Bloomberg
- Novo Nordisk Stock Plummets After Ozempic, Wegovy Maker Cuts U.S. Outlook Barron’s
Source link
